Nontoxic Goiter Workup
- Author: Stephanie L Lee, MD, PhD; Chief Editor: George T Griffing, MD more...
See the list below:
Assess all patients with goiter for thyroid dysfunction with a serum thyrotropin (TSH) assay. Second-generation or better TSH assays can detect clinically inapparent (subclinical) hyperthyroidism and hypothyroidism.
- If the TSH is high, consider chronic autoimmune thyroiditis (Hashimoto thyroiditis) or ingestion of a goitrogen, such as lithium or amiodarone, as well as dyshormonogenesis in a child. Correction of the hypothyroid status by withdrawal of the goitrogen or institution of thyroid hormone replacement therapy may greatly reduce the size of the goiter.
- If the TSH is low, measurement of serum free thyroxine (free T4) or free T4 index and total triiodothyronine (T3) is used to confirm the diagnosis of thyrotoxicosis. After many years, a nontoxic goiter may develop areas of functional autonomy (as seen in the image below) and thyrotoxicosis. Treatment of thyrotoxicosis includes stabilization of the hyperthyroid state with antithyroid medications and then surgical removal of the goiter or the administration of radioactive iodine ablative therapy.
Areas of autonomy with excess thyroid hormone secretion in a large nodular goiter. This technetium-99m (99mTc) thyroid scan shows hot and cold nodules in a multinodular goiter. Although the patient's thyroid-stimulating hormone level had become progressively suppressed, it was within the reference range, at 0.4 mU/mL (reference range 0.35-5.5 mU/mL).
Assessment of size and extent of the goiter is necessary to determine if progressive growth of the thyroid is occurring. Clinical assessment by an experienced clinician is often accurate until the thyroid increases to 4-5 times the normal size.
Measurement of neck circumference is a crude measure of thyroid size. Ultrasonography is good for estimating the number, size, and sonographic characteristics of nodules but is inaccurate in the clinical setting for measuring the volume of large goiters. Suspicious ultrasound characteristics, including hypoechogenicity, microcalcifications, macrocalcifications, intranodular vascularity, taller-than-wide dimensions, and blurred margins, guide the clinician as to which nodule requires biopsy for malignancy.[2, 1] Computed tomography (CT) scanning and magnetic resonance imaging (MRI), although expensive, are excellent for assessing tracheal compression and intrathoracic extension of the goiter.
A barium swallow may be used to document esophageal obstruction in patients with significant symptoms of dysphagia.
Thyroid scintigraphy is not routinely indicated in the assessment of goiter size unless a concern of thyroid hemiagenesis exists or the TSH is suppressed consistent with hyperthyroidism. A nodule with equivocal findings on thin-needle aspiration may be further evaluated using thyroid scintigraphy. A hot area supports the presence of a benign lesion. Examples of technetium-99m (99m Tc) thyroid scans are shown below.[2, 1]
See the list below:
Pulmonary function tests may be used as a functional assessment of tracheal compression. Characteristic changes of external tracheal compression can be detected in flow-volume loop tracings in asymptomatic patients with goiter. Direct laryngoscopy can, as indicated in the image below, also demonstrate tracheal compression.
A subset of patients presenting with goiter who do not have hyperthyroidism or has a cold nodule on nuclear thyroid scan with hyperthyroidism should have a fine-needle aspiration biopsy as the first diagnostic procedure. Clinical indication for biopsy includes suspicious sonographic characteristics listed above,asymmetrical and/or rapid growth of a nodule or lobe of a thyroid gland or unilateral adenopathy. Generally, in patients with the usual nonnodular nontoxic goiter that is long-standing with slow growth, fine-needle biopsy is not necessary unless sonographically suspicious nodules are present.[2, 1]
A variety of features may be observed with fine-needle aspiration cytology of a multinodular goiter. This variation is mostly explained by different stages of nodule formation. A proliferative phase exists in which the sample may contain many follicular cells. This can sometimes be difficult to distinguish from a follicular adenoma versus a follicular carcinoma. Colloid is another prominent feature. It represents the stored thyroid hormone within the follicle. Its absence suggests a more worrisome diagnosis.
After proliferation of follicular cells, a hemorrhage may occur inside the nodule. Erythrocytes and foamy macrophages that have ingested colloid material may be observed. Another potential area of concern is an aspiration that only returns cyst contents, ie, erythrocytes and macrophages without follicular cells. This cannot be used to definitively rule out the presence of thyroid cancer, and a reaspiration should be performed.
Bahn RS, Castro MR. Approach to the patient with nontoxic multinodular goiter. J Clin Endocrinol Metab. 2011 May. 96(5):1202-12. [Medline].
Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009 Nov. 19(11):1167-214. [Medline].
Baloch ZW, LiVolsi VA. Fine-needle aspiration of the thyroid: today and tomorrow. Best Pract Res Clin Endocrinol Metab. 2008 Dec. 22(6):929-39. [Medline].
Agarwal G, Aggarwal V. Is total thyroidectomy the surgical procedure of choice for benign multinodular goiter? An evidence-based review. World J Surg. 2008 Jul. 32(7):1313-24. [Medline].
Weetman AP. Radioiodine treatment for benign thyroid diseases. Clin Endocrinol (Oxf). 2007 Jun. 66(6):757-64. [Medline].
Baczyk M, Pisarek M, Czepczynski R, Ziemnicka K, Gryczynska M, Pietz L, et al. Therapy of large multinodular goitre using repeated doses of radioiodine. Nucl Med Commun. 2009 Mar. 30(3):226-31. [Medline].
Bonnema SJ, Hegedus L. A 30-year perspective on radioiodine therapy of benign nontoxic multinodular goiter. Curr Opin Endocrinol Diabetes Obes. 2009 Oct. 16(5):379-84. [Medline].
Duntas LH, Cooper DS. Review on the occasion of a decade of recombinant human TSH: prospects and novel uses. Thyroid. 2008 May. 18(5):509-16. [Medline].
Medeiros-Neto G, Marui S, Knobel M. An outline concerning the potential use of recombinant human thyrotropin for improving radioiodine therapy of multinodular goiter. Endocrine. 2008 Apr. 33(2):109-17. [Medline].
Braverman L, Kloos RT, Law B Jr, Kipnes M, Dionne M, Magner J. Evaluation of various doses of recombinant human thyrotropin in patients with multinodular goiters. Endocr Pract. 2008 Oct. 14(7):832-9. [Medline].
Fast S, Nielsen VE, Grupe P, et al. Optimizing 131I uptake after rhTSH stimulation in patients with nontoxic multinodular goiter: evidence from a prospective, randomized, double-blind study. J Nucl Med. 2009 May. 50(5):732-7. [Medline].
Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011 Jun. 21(6):593-646. [Medline].
Yetkin G, Uludag M, Onceken O, et al. Does unilateral lobectomy suffice to manage unilateral nontoxic goiter?. Endocr Pract. 2010 Jan-Feb. 16(1):36-41. [Medline].
Phitayakorn R, McHenry CR. Follow-up after surgery for benign nodular thyroid disease: evidence-based approach. World J Surg. 2008 Jul. 32(7):1374-84. [Medline].
Barczynski M, Konturek A, Hubalewska-Dydejczyk A, et al. Five-year Follow-up of a Randomized Clinical Trial of Total Thyroidectomy versus Dunhill Operation versus Bilateral Subtotal Thyroidectomy for Multinodular Nontoxic Goiter. World J Surg. 2010 Feb 20. [Medline].
Worni M, Schudel HH, Seifert E, et al. Randomized controlled trial on single dose steroid before thyroidectomy for benign disease to improve postoperative nausea, pain, and vocal function. Ann Surg. 2008 Dec. 248(6):1060-6. [Medline].
Erbil Y, Barbaros U, Temel B, et al. The impact of age, vitamin D(3) level, and incidental parathyroidectomy on postoperative hypocalcemia after total or near total thyroidectomy. Am J Surg. 2009 Apr. 197(4):439-46. [Medline].
Berghout A, Wiersinga WM, Drexhage HA, et al. Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre. Lancet. 1990 Jul 28. 336(8709):193-7.
Bonnema SJ, Bertelsen H, Mortensen J, et al. The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab. 1999 Oct. 84(10):3636-41. [Medline]. [Full Text].
Braverman LE, Utiger RD, Hermus AR, Huysmans DA:. Clinical manifestations and treatment of nontoxic diffuse and nodular goiter. In: Werner & Ingbar's The Thyroid. Baltimore, Md: Lippincott Williams & Wilkins;. 2000. 866-871.
Hegedus L, Gerber H. Multinodular goiter. In: DeGroot LJ, Jameson JL, eds. Endocrinology. 2001. 2:1517-1528.
Hermus AR, Huysmans DA. Treatment of benign nodular thyroid disease. N Engl J Med. 1998 May 14. 338(20):1438-47. [Medline].
Hollowell JG, Staehling NW, Hannon WH, et al. Iodine nutrition in the United States. Trends and public health implications: iodine excretion data from National Health and Nutrition Examination Surveys I and III (1971-1974 and 1988-1994). J Clin Endocrinol Metab. 1998 Oct. 83(10):3401-8. [Medline]. [Full Text].
Huysmans D, Hermus A, Edelbroek M, et al. Radioiodine for nontoxic multinodular goiter. Thyroid. 1997 Apr. 7(2):235-9. [Medline].
Huysmans DA, Hermus AR, Corstens FH, et al. Large, compressive goiters treated with radioiodine. Ann Intern Med. 1994 Nov 15. 121(10):757-62. [Medline].
Huysmans DA, Nieuwlaat WA, Erdtsieck RJ, et al. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter. J Clin Endocrinol Metab. 2000 Oct. 85(10):3592-6. [Medline]. [Full Text].
Netterville JL, Coleman SC, Smith JC, et al. Management of substernal goiter. Laryngoscope. 1998 Nov. 108(11 Pt 1):1611-7. [Medline].
Perrild H, Hansen JM, Hegedus L. Triiodothyronine and thyroxine treatment of diffuse non-toxic goitre evaluated by ultrasonic scanning. Acta Endocrinol (Copenh). 1982 Jul. 100(3):382-7. [Medline].
Ross DS. Thyroid hormone suppressive therapy of sporadic nontoxic goiter. Thyroid. 1992 Fall. 2(3):263-9. [Medline].